` AVR (Anteris Technologies Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

AVR
vs
S&P/ASX 300

Over the past 12 months, AVR has underperformed S&P/ASX 300, delivering a return of -52% compared to the S&P/ASX 300's 11% growth.

Stocks Performance
AVR vs S&P/ASX 300

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
AVR vs S&P/ASX 300

Loading
AVR
S&P/ASX 300
Difference

Performance By Year
AVR vs S&P/ASX 300

Loading
AVR
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Anteris Technologies Ltd vs Peers

S&P/ASX 300
AVR
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Anteris Technologies Ltd
Glance View

Market Cap
324.2m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.52 AUD
Overvaluation 94%
Intrinsic Value
Price
Back to Top